enpicom

Models & Molecules

Business EN ↓ 6 episodes

At the intersection of computation and biology, Models & Molecules explores how data, algorithms, and science come together to design the medicines of tomorrow. Each episode features candid conversations with the people shaping this transformation, from pharma R&D leaders to computational biologists and AI innovators. Produced by ENPICOM, Models & Molecules offers a rare look behind the buzzwords of AI-driven discovery, uncovering the practical realities, lessons learned, and moments of insight that emerge when biology meets computation.

Author

enpicom

Category

Business

Podcast website

enpicom.com

Latest episode

Jun 2, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 5M+ downloads · 4.8 rating iOS soon

Episodes

Talip Uçar | Inside Boltz's open-source bet on the future of AI-driven drug discovery 02.06.2026

When an AI model generates an image, you can tell at a glance whether it's any good. In life sciences, that feedback loop is fragmented across data, modelling, experiments, and the clinic, and signal gets lost at every handoff. In this episode, we sit down with Talip Uçar, founding member of Boltz, to discuss why data is the real competitive advantage, why pharma needs a tech-first mindset to...

Steve Comeau | From novel binder design to the realities of AI in complex therapeutics 14.04.2026

Generative models can now propose novel antibody sequences from antigen structure alone, but how far does that actually get you? In this episode, we sit down with Principal Scientist Steve Comeau to discuss what current models can realistically deliver, where the data falls short, and why the harder problems are still ahead of us. Read the full conversation: ⁠⁠https://enpicom.com/models-molecules/...

Jiwon Kim | From lab-in-the-loop to zero-shot: The role of cloud and AI agents 03.03.2026

Jiwon Kim, Product Lead at AWS AI Life Sciences, joins Models & Molecules to break down pharma’s digital shift: where cloud and software are becoming core infrastructure for modern drug discovery. We touch upon the potential of agentic AI, why zero-shot models are the future, why lab in the loop is the essential bridge for getting there. Read the full conversation: ⁠https://enpicom.com/models-...

Do Soon Kim | Navigating the convergence of tech and pharma 28.01.2026

In this episode of Models & Molecules, Do Soon Kim, Head of Product at Xaira Therapeutics, discusses his journey in the biotech and AI sectors, emphasizing the importance of effective communication in fostering collaboration between different scientific disciplines. The conversation explores the potential of machine learning to reshape our understanding of intelligence and moving beyond the li...

Jaap Goudsmit | From rabies to COVID: Antibody discovery in the age of AI 16.12.2025

In this episode of Models & Molecules, Jaap Goudsmit, MD, PhD, immunologist, epidemiologist, and one of the scientific forces behind Crucell, the Dutch biotech acquired by Johnson & Johnson, explores the critical evolution of antibody research. Jaap reflects on the journey from traditional discovery to the complexities of modern drug development, highlighting the transformative role of AI...

René Hoet | Taking risks and driving innovation in biopharma 04.11.2025

In this episode of Models & Molecules, René Hoet reflects on game-changing technologies like phenotypic screening, the unique innovation dynamics of small biotechs versus large pharma, and the real-world impact of AI in antibody discovery. We touch upon bridging academia and industry and discuss why taking calculated risks is essential for the next breakthroughs in drug discovery. Read the ful...

Listen to the Models & Molecules podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.